White & Case Partner Rebecca H. Farrington
As the pharmaceutical industry has been on an M&A binge lately, White & Case Partner Rebecca H. Farrington has been taking part, working on the team that advised China-based Shenzhen Hepalink Pharmaceutical Co. Ltd, and its U.S. subsidiary Hepalink USA Inc. on the $337.5 million acquisition of Scientific Protein Laboratories, LLC.
The transaction closed on April 9, after the parties obtained the necessary antitrust and regulatory approvals and clearances in the People’s Republic of China, the United States and France, according to White & Case.
The combined company has an expanded presence as one of the leading suppliers of heparin worldwide, as well as greater product development and growth opportunities in new markets for its full line of active pharmaceutical ingredients, including pancreatic enzyme and heparin products.
The White & Case team that advised Shenzhen Hepalink was led by partner Alex Zhang (Shanghai). Along with Farrington, who is based in Washington, D.C., the team included partners Daniel Latham (New York), George Paul, Richard Burke (Washington, D.C.) and Jean-Paul Tran Thiet (Paris). Dovrat Bashan (New York), Ning Zhang (Shanghai), Orion Berg (Paris) and Jérémie Jourdan (Brussels) also supported the team on the deal.
A member of White & Case’s Global Antitrust/Competition Practice, Farrington’s practice focuses on government merger and nonmerger investigations, private antitrust litigation and counseling clients on antitrust issues. She also counsels clients on the premerger notification filing requirements and related antitrust issues of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).